📰 Given Maxcyte News
Given Maxcyte News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Given Maxcyte. Real-time updates on events, politics, business and more.
January 24, 2024
OneMedNet (NASDAQ:ONMD – Get Free Report) and MaxCyte (NASDAQ:MXCT – Get Free Report) are both small-cap computer and technology companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, valuation, risk and analyst recommendations. Insider and Institutional Ownership 35.4% of OneMedNet […]
September 25, 2023
MaxCyte (NASDAQ:MXCT – Get Free Report) and FOXO Technologies (NYSE:FOXO – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, profitability, earnings and risk. Risk and Volatility MaxCyte has a beta of […]
April 19, 2023
MaxCyte (NASDAQ:MXCT – Get Rating) and Incyte (NASDAQ:INCY – Get Rating) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation. Analyst Ratings This is a summary of current ratings for MaxCyte and […]
June 10, 2022
MaxCyte (NASDAQ:MXCT – Get Rating) is one of 40 public companies in the “Commercial physical research” industry, but how does it contrast to its rivals? We will compare MaxCyte to similar companies based on the strength of its valuation, risk, analyst recommendations, dividends, profitability, earnings and institutional ownership. Institutional and Insider Ownership 65.9% of MaxCyte […]
June 5, 2022
MaxCyte (NASDAQ:MXCT – Get Rating) is one of 40 public companies in the “Commercial physical research” industry, but how does it contrast to its peers? We will compare MaxCyte to related businesses based on the strength of its analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends. Insider & Institutional Ownership 65.9% of MaxCyte […]
June 4, 2022
MaxCyte (NASDAQ:MXCT – Get Rating) is one of 40 public companies in the “Commercial physical research” industry, but how does it contrast to its peers? We will compare MaxCyte to similar companies based on the strength of its dividends, institutional ownership, profitability, analyst recommendations, risk, valuation and earnings. Analyst Ratings This is a summary of […]
June 2, 2022
MaxCyte (NASDAQ:MXCT – Get Rating) is one of 40 publicly-traded companies in the “Commercial physical research” industry, but how does it compare to its peers? We will compare MaxCyte to related businesses based on the strength of its institutional ownership, analyst recommendations, profitability, valuation, risk, dividends and earnings. Earnings & Valuation This table compares MaxCyte […]
June 2, 2022
MaxCyte (NASDAQ:MXCT – Get Rating) is one of 40 publicly-traded companies in the “Commercial physical research” industry, but how does it weigh in compared to its competitors? We will compare MaxCyte to similar businesses based on the strength of its dividends, analyst recommendations, risk, profitability, earnings, valuation and institutional ownership. Earnings & Valuation This table […]
May 31, 2022
MaxCyte (NASDAQ:MXCT – Get Rating) is one of 40 public companies in the “Commercial physical research” industry, but how does it weigh in compared to its peers? We will compare MaxCyte to related companies based on the strength of its institutional ownership, analyst recommendations, valuation, risk, earnings, profitability and dividends. Analyst Ratings This is a […]
May 31, 2022
MaxCyte (NASDAQ:MXCT – Get Rating) is one of 40 publicly-traded companies in the “Commercial physical research” industry, but how does it contrast to its competitors? We will compare MaxCyte to similar businesses based on the strength of its earnings, valuation, dividends, risk, institutional ownership, profitability and analyst recommendations. Analyst Recommendations This is a breakdown of […]